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Original ArticleSpatiotemporal PET Imaging Reveals
Differences in CAR-T Tumor Retention
in Triple-Negative Breast Cancer Models
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1Imaging Therapies and Cancer Group, Department of Imaging Chemistry and Biology, School of Biomedical Engineering and Imaging Sciences, King’s College London,
London, UK; 2Department of Imaging Chemistry and Biology, School of Biomedical Engineering and Imaging Sciences, King’s College London, London, UKChimeric antigen receptor T cell therapy (CAR-T) has been
rolled out as a new treatment for hematological malignancies.
For solid tumor treatment, CAR-T has been disappointing so
far. Challenges include the quantification of CAR-T trafficking,
expansion and retention in tumors, activity at target sites, tox-
icities, and long-term CAR-T survival. Non-invasive serial
in vivo imaging of CAR-T using reporter genes can address
several of these challenges. For clinical use, a non-immuno-
genic reporter that is detectable with exquisite sensitivity by
positron emission tomography (PET) using a clinically avail-
able non-toxic radiotracer would be beneficial. Here, we em-
ployed the human sodium iodide symporter to non-invasively
quantify tumor retention of pan-ErbB family targeted CAR-T
by PET. We generated and characterized traceable CAR
T cells and examined potential negative effects of radionuclide
reporter use. We applied our platform to two different triple-
negative breast cancer (TNBC) models and unexpectedly
observed pronounced differences in CAR-T tumor retention
by PET/CT (computed tomography) and confirmed data
ex vivo. CAR-T tumor retention inversely correlated with im-
mune checkpoint expression in the TNBC models. Our plat-
form enables highly sensitive non-invasive PET tracking of
CAR-T thereby addressing a fundamental unmet need in
CAR-T development and offering to provide missing informa-
tion needed for future clinical CAR-T imaging.Received 17 December 2019; accepted 24 June 2020;
https://doi.org/10.1016/j.ymthe.2020.06.028.
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Chimeric antigen receptor (CAR) T cell therapy (CAR-T) relies on
the genetic modification of a patient’s T cells to express artificial
plasma membrane receptors with specificities against the patient’s
cancer. This immunotherapy approach has resulted in unprecedented
clinical outcomes in certain hematological cancers and is now in
routine clinical use.1–4 However, in solid tumors CAR-T has been
disappointing due to barriers in CAR-T tumor infiltration, as well
as the impairment of CAR T cell efficacy by metabolic stresses, im-
mune checkpoint molecules, and/or cytokines rendering them
apoptotic, exhausted, or anergic.5 Notably, CAR T cell longevity, dis-
tribution, and potential re-distribution, as well as their overall sur-Molecu
This is an open access article under the CC BY-NC-Nvival across tumor sites and other tissues, are critical parameters
that need careful evaluation before these therapeutics can reach their
full potential in solid tumors. For example, on-target off-site effects
have led to severe adverse events6,7 and been associated with life-
threatening side-effects and fatalities in clinical trials.8,9 Nevertheless,
clinical trials are still largely performed without knowledge about the
in vivo distribution and fate of the administered CAR T cells, making
it is impossible to adequately assess their in vivo distribution, safety,
and fate.
Importantly, non-invasive cell tracking using sensitive whole-body
in vivo imaging has great potential to aid CAR-T development and
clinical application by elucidating several of the above aspects.10–12
Multi-modality imaging combining radionuclide technologies such
as single-photon computed tomography (SPECT) or positron emis-
sion tomography (PET) with anatomical imaging by either computed
tomography (CT) or magnetic resonance imaging (MRI) has great
potential in this context. Current clinical instrumentation for PET
is superior to SPECT in both sensitivity and resolution.13,14 Cells
need to be rendered in vivo traceable over days/weeks. Therefore, ge-
netic engineering to ectopically express a reporter gene that enables
contrast formation in vivo upon administration of a matching
contrast agent holds great promise (e.g., a reporter protein enabling
the uptake or the binding of a contrast agent).12,15 Radionuclide re-
porter genes suitable for immune cell imaging must be non-immuno-
genic while providing excellent contrast and be endogenously ex-
pressed only in a very limited number of tissues and ideally at lowlar Therapy Vol. 28 No 10 October 2020 ª 2020 The Authors. 2271
D license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Generation of Reporter Expressing pan-ErbB Family CAR T Cells
(A) Scheme of the construct platform developed for combined gene transfer of CAR,
reporter, and auxiliary genes. Expression is driven from the spleen focus-forming
virus promoter (PSFFV). Selective expansion of clones is enabled by 4ab. The
functional CAR is T1E28z while the truncated CAR T1E28Dz is functionally deficient.
The radionuclide reporter NIS is fused to the fluorescent protein mTagRFP (TRFP) in
these preclinical cassettes; for clinical applications, the fluorescent protein can be
omitted. Proteins are separated by self-cleaving peptide sequences (T2A), whereby
trimming of the 4ab to remove T2A remnants was enabled via an additional furin site.
(B) Exposure with corresponding viruses resulted in transduction of primary human
T cells as assessed by flow cytometry. Selection of positively transduced clones
using IL-4 permitted significant enrichment of CAR-T cells without the need of FACS
sorting. (C and D) Phenotypes of transduced T4NT CAR T cells after selection
demonstrating purity of T cell features (CD3) and the ratio of CD4+ and CD8+ T cells.
CD4+:CD8+ dependent on donors (see Figure S2 for examples). Typical data are
shown in (B)–(D).
Molecular Therapylevels to achieve good contrast.11 Few proteins fulfil these criteria with
a prostate-specific membrane antigen variant (tPSMAN9del)16 and the
human sodium iodide symporter (NIS)17 being the most promising,
both of which have previously been used before for tracking cytolytic
T cells. Both can be matched with clinically used/trialed PET contrast
agents, although T cell tracking by PET has not yet been demon-
strated for NIS.
Several CAR-Twith diverse targets have been trialed for the treatment
of solid tumors,18 but none has been approved for clinical use yet.
Among these targets are the epidermal growth-factor receptors
(ErbB family), which can be pharmacologically targeted (e.g., small
molecules, antibodies) but this has frequently resulted in resistance
and subsequent therapeutic failure. Consequently, a broadly appli-
cable CAR-based immunotherapy was developed, the T1E28z CAR,
in which the propensity of solid tumors to dysregulate the ErbB recep-
tor family network was targeted.19 The T1E28z CAR is already trialed
clinically in head and neck cancer (NCT01818323), although applied
intratumorally rather than systemically due to potential safety con-2272 Molecular Therapy Vol. 28 No 10 October 2020cerns. This immunotherapy could also be applicable for difficult-to-
treat triple-negative breast cancers (TNBC)20 ormesothelioma,21 pro-
vided in vivo distribution and fate of this immunotherapy are better
understood.
Here, we developed a platform enabling highly sensitive non-inva-
sive in vivo PET tracking of CAR-T using NIS. We applied it to
the T1E28z CAR to determine CAR-T retention in TNBC xenograft
models. Our aims were to provide a tool and demonstrate its appli-
cation to facilitate preclinical development of new CARs and to sup-
port with this clinically compatible tool future clinical CAR-T
imaging.
RESULTS
Generation of Reporter Gene-Expressing Pan-ErbB Family-
Targeted CAR T Cells
We built a platform for co-expression of a CAR and a radionuclide-
fluorescence reporter gene, wherein the radionuclide reporter enables
non-invasive in vivo cell tracking and the fluorescence reporter facil-
itates CAR T cell generation. As a CAR, we used the locally developed
multi-specific pan-ErbB T1E28z CAR, which targets most homo- and
heterodimers of ErbB family members.19 Additionally, we included
the previously reported interleukin-4Ra (IL-4Ra):IL-2/15Rb chimera
(4ab) intended for selective expansion of transduced CAR T cells in
the presence of IL-4.22 This was previously combined with the T1E28z
CAR using 2A technology,23 demonstrating that the resultant short
N-terminal Pro-Met addition impaired neither CAR trafficking to
the plasma membrane nor CAR function. To additionally include
the radionuclide-fluorescence fusion reporter human NIS-mono-
meric TagRFP (NIS-RFP), which was previously characterized,24 we
also aimed to utilize a 2A cleavage peptide. Therefore, we first vali-
dated the extent to which NIS-RFP would tolerate N-terminal mod-
ifications and found that the minimal possible modification, Pro-Met,
did not impair NIS function (Figure S1). We then generated lentiviral
vectors for the transfer of expression cassettes including 4ab and the
T1E28z CAR with or without the NIS-RFP reporter (T4NT and T4,
respectively; Figure 1A). As an additional control, we generated a
non-functional CAR lacking the CD3z domain and implemented it
within the platform at the expense of T1E28z (T4DNT; Figure 1A).
Lentiviruses were produced from these constructs and used to trans-
duce purified human T cells, which were subsequently cultured in the
presence of IL-4 to selectively expand CAR T cells (exploiting 4ab) as
previously reported.22 CD4+/CD8+ ratios depended on human do-
nors (typical example of CAR T cells: Figures 1C and 1D; all batches
Figure S2). The expansion characteristics of T4NT and T4DNT CAR
T cells in the presence of IL-4 was comparable to the proliferation of
untransduced T cells in the presence of IL-2, demonstrating no major
impact on growth after transduction (Figure S3).
In Vitro Characterization of Pan-ErbB Family-Targeted CAR
T Cells
For correct function of both NIS-RFP reporter and CAR, it was
important that these proteins were localized at the cellular plasma
membrane. Using confocal microscopy, we found for all CARs and
Figure 2. In Vitro Characterization of Traceable pan-
ErbB Family CAR T Cells
(A) Confocal microscopy demonstrated correct plasma
membrane localization of the CAR and the NIS-RFP fusion
reporter through co-localization with the plasmamembrane
marker WGA (conjugated to the fluorophore Alexa-
Fluor488). Typical micrographs are shown; scale bars is
10 mm, image dimensions are identical for all images. (B)
NIS-RFP reporter function in T4NT CAR T cells was vali-
dated by uptake of either the PET radiotracer [18F]BF4
 or
the SPECT radiotracer - [99mTc]TcO4
. Uptake was com-
parable with the two different NIS radiotracers and was
0.13 ± 0.01 and 0.13 ± 0.03, for [18F]BF4
 and [99mTc]
TcO4
 respectively, compared to larger cancer cells over-
expressing NIS-RFP,24 which served as experimental
reference. CAR T cells lacking the reporter (T4) did not
show any radiotracer uptake. Error bars are SD; n = 3
different CAR T cells batches generated from different do-
nors. (C and D) Validation of CAR function by BCC mono-
layer killing assays. (C) BCC cell viability was assessed after
incubation with indicated CAR T cells or T cells alone, as
indicated. A negative control (black) was obtained by not
adding immune cells. Addition of the reporter NIS-RFP did
not impact CAR function (no difference between red and
yellow) while dysfunctional CAR (red-brown) and un-
transduced T cells (gray) did not mediate tumor cell killing.
Error bars are SD; nR 3 different CAR T cell batches each.
(D) Cell death was determined in the presence of different
amounts of either T4NT or untransduced T cells from the
same batches (1:1 or 10:1) at the indicated time points.
Error bars are SD; n = 3 independent experiments. Signif-
icant differences compared to untransduced T cell experi-
ments at same ratios indicated as *p < 0.05, **p < 0.01,
***p < 0.001.
www.moleculartherapy.orgthe NIS-RFP reporter the expected cellular localization patterns on
T cell plasmamembranes as indicated by co-localization with the gen-
eral plasma membrane marker wheat germ agglutinin (WGA;
Figure 2A).
Furthermore, uptake of either the SPECT radiotracer [99mTc]TcO4
–
or the PET radiotracer [18F]BF4
– revealed correct reporter gene func-
tion in T4NT CAR T cells (Figure 2B), a pre-requisite for in vivo
tracking of these cells. Notably, [99mTc]TcO4
– and [18F]BF4
– dis-
played similar relative uptake values compared to a reference
cancer cell line expressing high reporter levels (Figure 2B;24).
Repeated radiotracer uptake in the same T4NT cells also resulted in
comparable cellular radioactivity levels (Figure S4). The latter demon-
strated that even with the longer half-life radiotracer ([99mTc]TcO4
–
Molec[t1/2(
99mTc) = 6.01 h versus t1/2(
18F) =
110 min]) repeat measurements 24 h apart were
feasible without radiotracer from the first uptake
affecting uptake measurements of a second up-
take experiment. Control CAR T cells lacking
the radionuclide reporter (T4) did not take up
the radiotracers, thereby demonstrating speci-
ficity of the assay (Figure 2B). These results pro-vided a rationale for the interchangeable use of both radiotracers for
the in vitro NIS functional characterization.
Next, we determined whether reporter expression affected the func-
tion of the pan-ErbB family-targeted CAR. Therefore, we determined
the cytotoxicity of T4NT CAR T cells and various control T cells to-
ward different human breast cancer cells (BCCs). We used BCC lines
that expressed different combinations of ErbB family proteins
including MDA-MB-231, MDA-MB-436 (both triple-negative, i.e.,
HER2–/ER–/PR–), MCF-7, and HCC1954 cells (for relative ErbB fam-
ily receptor status, see Figure S5). Cell killing of BCC monolayers was
assessed after addition of either T4NT (functional CAR), T4DNT
(non-functional CAR), T4 (functional CAR but no reporter), or un-
transduced T cells (no CAR and no reporter). Results confirmedular Therapy Vol. 28 No 10 October 2020 2273
Figure 3. Quantification of Radiotracer Impact on
In Vivo Traceable T4NT CAR T Cells
(A) CAR T cell viability as assessed by Alamar Blue fluo-
rescence. Cells were radiolabeled with the indicated NIS
radiotracers; error bars are SD; n = 3 different experiments.
(B) T4NT CAR T cell function was determined in cancer cell
monolayer killing assays with indicated breast cancer cell
lines (over 72 h post T4NT radiolabeling). T4NT CAR T cells
were either not radiolabeled (white) or radiolabeled with the
indicated NIS radiotracers; untransduced T cells served as
negative control. (C) T4NT CAR T cell function as quanti-
fied by interferon-g release (by ELISA 72 h after addition of
radiolabeled T4NT to monolayers); T4NT treated as in (B).
For both (B) and (C), error bars represent SD from n = 3
different T4NT batches. (D, left) DNA damage in radio-
labeled T4NT CAR T cells. T4NT were radiolabeled with
[99mTc]TcO4
 resulting in the listed amounts of cellular
radioactivity (shades of blue). Unlabelled cells served as
controls (white). Cells were fixed at indicated time points
after radiotracer administration and stained for double
strand breaks (detected as gH2AX foci), which were
counted per cell. (D, right) Untransduced T cells (striped)
were exposed to identical settings and conditions as
T4NT in (D, left). (E) Analogous experiment as in (D) but with
[18F]BF4
. For (D) and (E), error bars are SD; n = 3 with a
total >35 cells each. Significant differences (p < 0.05) be-
tween highest dose at 2 h and ($) lower doses at the same
time point, (#) same dose at later time points (24 h, 72 h),
and (&) all samples with untransduced T cells.
Molecular TherapyCAR-mediated BCC killing in the presence of functional CARs (Fig-
ure 2C) and that the reporter NIS-RFP did not negatively impact on
CAR function (Figure 2C; no significant differences between yellow
and red bars). While in Figure 2C the quantified parameter was
BCC survival, we complemented this data with direct measurements
of cell death, which also showed T4NT-mediated BCC killing in a
dose-dependent manner (Figure 2D).
In summary, these data demonstrated correct function of both CAR
and reporter and that the reporter did not impact on CAR function or
T cell proliferation.
Effects of Radiotracer Uptake and Decay on CAR T Cells
Importantly, the uptake of radiotracers has the potential to exert radi-
ation-induced DNA damage and thereby negatively impact on the
cells taking themup.We first investigated whether CART cell viability
was affected by radiotracer uptake. Therefore, T4NTCART cells were
exposed to either [99mTc]TcO4
– or [18F]BF4
– and cell viability was
quantified five days after radiotracer uptake, at a time point when all2274 Molecular Therapy Vol. 28 No 10 October 2020radioactivity had decayed, and the cells had
received the full dose.We did not find any signif-
icant impact on T4NT CAR T cell viability upon
uptake of either radiotracer (Figure 3A).
Furthermore, we quantified whether CAR
T cells were affected in their BCC killing func-tion by radiolabeling. We subjected the same BCC lines as in Fig-
ure 2B to T4NT CAR T cells that had been incubated with either
[99mTc]TcO4
, [18F]BF4
, or vehicle, and found no differences in
their tumor cell killing capacity (Figure 3B). Active CAR T cells
also release interferon-g into the cell culture medium upon tumor
cell killing. Notably, we did not find any significant differences be-
tween CAR T cells that were exposed to radiotracers or vehicle
(Figure 3C).
Next, we determined the level of radiation-induced DNA damage
to CAR T cells. Therefore, we exposed T4NT CAR T cells to the
longer half-life radiotracer [99mTc]TcO4
 or vehicle, and stained
cell aliquots for the double-strand break (DSB) marker gH2AX.
At the highest administered radiotracer level, which resulted
in 130 mBq [99mTc]TcO4
– per cell after uptake, we found a
significantly increased number of DSB foci per cell 2 h after radio-
tracer administration compared to cells that had received no
radioactivity (Figure 3D/left). At lower administered radioactivity
levels resulting in 51 mBq [99 mTc]TcO4
 per cell, a similar trend
Figure 4. Detection Sensitivity of T4NT CAR T Cells
(Top) PET images of indicated CAR T cell numbers acquired 15 minutes after ra-
diolabeling with [18F]BF4
 (see Materials and Methods). Typical images are shown
from one T4NT batch. (Bottom) Cumulative analysis of obtained imaging data from
three T4NT batches (error bars are SD). Dashed line indicates background signals,
with gray shade indicating background mean ± three times SD. The limit of
detection was defined as background mean plus three times SD of the background
mean and is marked by the upper dotted line. Cell detection limit is ~3,000 T4NT
CAR T cells.
www.moleculartherapy.orgwas observed; when we analyzed the top 15% reporter-expressing
T4NT CAR T cells from the population separately (as determined
by fluorescence microscopy during the assay), differences were
significant to vehicle-treated T4NT cells, indicating dose depen-
dency (Figure S6A). At all lower radioactivity levels, there was
no change compared to vehicle-treated cells. Importantly, the
observed radiation-induced DSBs were repaired in the cells over
time, resulting in no changes between DSB foci per cell after
24 h or 72 h after radiotracer administration (Figure 3D, left).
Notably, untransduced T cells from the same batch, which lacked
the reporter NIS-RFP, did not take up radioactivity and also did
not show any increase in DSB foci, even when exposed to the
highest level of radioactivity (Figure 3D, right). Moreover, we
performed analogous experiments with the shorter half-life PET
radiotracer [18F]BF4
– for which we obtained similar results
(Figure 3E).
These data demonstrated that the consequences of NIS use, i.e.
cellular uptake of both NIS imaging radiotracers ([99mTc]TcO4

and [18F]BF4
) and the dose received by cells due to their com-
plete decay, did not negatively impact on CAR T cell function or
viability. In summary, this validated the approach and provided
the basis for subsequent in vivo imaging.Non-invasive Determination of CAR T Cell Retention in TNBC
Models
First, we established detectability of traceable T4NT CAR T cells on
our PET instrumentation. Therefore, we admixed different amounts
of T4NT CAR T cells to untransduced T cells, subjected each cell
mixture to an uptake assay with the PET radiotracer [18F]BF4
, and
quantified radioactivity signals on the PET scanner. Detection sensi-
tivity was determined to be just above 3,000 cells (Figure 4).
We then established orthotopic human xenograft TNBC models
using the well-characterized cell lines MDA-MB-436 and MDA-
MB-231.25 To decouple retention measurements from tumor target-
ing effects, we administered the CAR T cells intratumorally. Traceable
pan-ErbB T4NT CAR T cells were imaged in vivo by PET using the
radiotracer [18F]BF4
 to detect NIS-expressing CAR T cells, followed
by ex vivo analyses.
In MDA-MB-436 xenograft tumors, we detected by PET intratumor-
ally administered T4NT CAR T cells in tumors on the day after
administration (day 1) and also on subsequent imaging days (days
7 and week 2; Figure 5). Quantitation of in vivo imaging data revealed
that observed signals stemming from T4NT CAR T cells over the
2-week observation period were always significantly higher than in
control animals (Figure 5C) without major changes of signals within
tumors over time. These data were corroborated by ex vivo radioac-
tivity measurements by g-counting of whole tumors harvested after
two weeks, with tumors from animals that had received T4NT CAR
T cells showing significantly higher radioactivity levels compared to
tumors from control animals (Figure 5D).
Interestingly, in a second TNBC model, MDA-MB-231, we observed
a different behavior of the T4NT CAR T cells over time. T4NT CAR
T cells were detectable on the day after administration and for the
following time point, but signals in tumors were not significantly
different from control animals that did not receive CAR T cells after
two weeks (Figure 6). Ex vivo radioactivity measurements by g-count-
ing of whole tumors confirmed in vivo imaging results after two weeks
and demonstrated that there were no significant differences between
tumors that had received T4NT CAR T cells and control tumors (Fig-
ure 6D). We performed additional experiments with dedicated co-
horts culled after administration and after two weeks, respectively,
and subjected harvested tumors to ex vivo g-counting measurements
and histology. Results confirmed our data from in vivo imaging exper-
iments demonstrating that radioactivity signals from T4NT CAR
T cells, as well as their presence in tissues (determined by anti-human
CD3 staining), were only detectable in tumors at the first time point
(Figures 7A–7C). Overall, there was no effect of CAR T cell adminis-
tration on tumor sizes in MDA-MB-231 models (Figure S7), which
was in line with loss of therapeutic cells over time.
Together, these data clearly demonstrate a different behavior of the
pan-ErbB CAR T cells in these two TNBC xenograft models. As
host immunity is very low in NSG mice,26 this pointed toward differ-
ences likely to be intrinsic to the tumor cells.Molecular Therapy Vol. 28 No 10 October 2020 2275
Figure 5. Tracking T4NT CAR T Cell Retention in
MDA-MB-436 Xenograft Tumors
(A) Experimental scheme. (B) 5  106 T4NT CAR T cells
(red frame) or vehicle (blue frame) were intratumorally
administered (yellow arrows) on day zero and animals
were PET/CT imaged (5 MBq [18F]BF4
; 40 min post
administration) on indicated days. Endogenous signals
are recorded in the thyroid and salivary glands (Th+SG),
the stomach (S) and at much lower levels in some regions
of the mammary glands. Tracer excretion happened re-
nally, which is why in some animals, depending on their
bladder fill status before imaging, signals from the bladder
were recorded (B). T4NT CAR T cells are clearly visible in
the tumor in all imaging sessions. Anatomical imagines
(CT; grayscale) are overlayed with PET images (hue).
Coronal and sagittal slices from a representative animal
are shown; all PET images are on the same scale. (C)
Cumulative quantitative analysis of tumor radioactivity
from in vivo images of all animals. Box shows range from
25th to 75th percentile, whiskers minimum and maximum
values; each dot represents one mouse (red, T4NT; blue,
control). p values calculated by Mann-Whitney test. (D)
Ex vivo analysis of radioactivity in harvested tissues
quantified by g-counting. Cumulative data of indicated
organs from all animals are shown with error bars repre-
senting SEM. Inset shows zoom-in on tumors. p value
calculated by Mann-Whitney test.
Molecular TherapyIntratumoral CAR T Cell Infiltration and Expression of Immune
Checkpoints
Through in vivo imaging, we had also observed that T4NT CAR
T cells largely remained within MDA-MB-436 tumors, while they
were lost in MDA-MB-231 tumors over time. On day 3, we could still
detect few T4NT CAR T cells and interestingly the intratumoral
signal distribution appeared similar to day 1 (Figure 6B). Histology
of sections from early time points after administration further corrob-
orated this by revealing clear margins between tumor areas in which
T4NT CAR T cells were injected and adjacent areas, which did not
contain cells staining positive for human CD3 (Figure 7D). Tumor
cells were easily identifiable in these sections as MDA-MB-231 cells
expressing a plasma membrane-targeted GFP were employed
(MDA-MB-231.GFP-CaaX). Notably, T4NT CAR T cells appeared
to be active in regions where they were present as judged from the
loss of tumor cells (loss of GFP fluorescence) in these confined spaces.
Moreover, we systemically administered either T4NT CAR T cells or
untransduced T cells to animals with MDA-MB-231 tumors (Fig-
ure S8). We found that T4NT CAR T cells homed into tumors within2276 Molecular Therapy Vol. 28 No 10 October 202024 h of administration, but they did not uni-
formly infiltrate the tumor there.
Various immune checkpoints have emerged in
regulating anti-cancer T cell activity, thereby
providing a rationale for analyzing their poten-
tial expression differences between MDA-MB-
231 and MDA-MB-436 cells.27 We selectedseveral of them for analysis including the programmed death-ligand
1 (PD-L1), the TIM-3 ligands galectin-9 and CD66a/CAECAM-1,
the LAG-3 ligand HLA-DR (a representative of MHC class II), and
the T cell immunoreceptor with Ig (ITIM) and immunoreceptor tyro-
sine-based inhibition motif (TIGIT) domains ligands CD155/PVR
and CD112/nectin-2. Furthermore, we investigated potential differ-
ential expression of B7-H3, B7-H4, and B7-H5/VISTA. We found
significantly higher PD-L1 expression in MDA-MB-231 compared
to MDA-MB-436 cells (Figure 8A, top). Moreover, we found that a
higher percentage of MDA-MB-231 cells expressed CD112 but a
lower percentage of them expressed CD155, both of which are ligands
for TIGIT (Figure 8A, middle and bottom). There were also differ-
ences in the expression of the B7-class inhibitory molecules B7-H3
(a similar proportion of positive cells but at lower median fluores-
cence intensities; Figure 8, left and Figure S10) and B7-H4 (higher
expression in MDA-MB-231 cells; Figure 8, right). The other
analyzed molecules were not expressed in both cell lines (Figures
S11 and S12). As the observed PD-L1 differences were the most pro-
nounced, we also validated them independently by immunoblot
Figure 6. Tracking T4NT CAR T Cell Retention in
MDA-MB-231 Xenograft Tumors
(A) Experimental scheme. (B) 5  106 T4NT CAR T cells
(red frame) or vehicle (blue frame) were intratumorally
administered (yellow arrows) on day zero and animals
were PET/CT imaged (5 MBq [18F]BF4
; 40 min post
administration) on indicated days. Endogenous signals
are recorded in the thyroid and salivary glands (Th+SG),
the stomach (S) and at much lower levels in some regions
of the mammary glands. Tracer excretion happened re-
nally, which is why in some animals, depending on their
bladder fill status before imaging, signals from the bladder
were recorded (B). T4NT CAR T cells are clearly visible in
the tumor in all imaging sessions. Anatomical imagines
(CT; grayscale) are overlayed with PET images (hue).
Coronal and sagittal slices from a representative animal
are shown; all PET images are on the same scale. (C)
Cumulative quantitative analysis of tumor radioactivity
from in vivo images of all animals. Box shows range from
25th to 75th percentile, whiskers minimum and maximum
values; each dot represents one mouse (red, T4NT; blue,
control). p values calculated by Mann-Whitney test. (D)
Ex vivo analysis of radioactivity in harvested tissues
quantified by g-counting. Cumulative data of indicated
organs from all animals are shown with error bars repre-
senting SEM. Inset shows zoom-in on tumors. p value
calculated by Mann-Whitney test.
www.moleculartherapy.organalysis, which confirmed flow cytometry results (Figure S13). In
xenograft tumors established from these two TNBC cell lines, we
also found significant differences in PD-L1 staining between the
two models with higher staining in MDA-MB-231 tumors compared
to MDA-MB-436 tumors (Figure 8C). Notably, in MDA-MB-231 tu-
mors PD-L1 was predominantly found in the plasma membranes of
tumor cells suggesting PD-L1 availability for interaction with T cells.
Together, this data showed an inverse correlation between T4NT CAR
T cell retention and the immune checkpoint inhibitor PD-L1 expres-
sion in these two TNBC models. While PD-L1 was found to be the
most pronounced difference of the analyzed checkpoints, the TIGIT li-
gandsCD112 andCD155 and theB7-classmolecules B7-H3 andB7-H4
are likely to also contribute to the differences observed, highlighting the
multifactorial challenges facing CAR-T therapy in solid tumors.
DISCUSSION
Despite recent successes of CAR T cell therapy in hematologic malig-
nancies, there are still many challenges for its application to solidMolecutumors. To accelerate CAR T cell therapy devel-
opment and characterize emerging toxicities,
non-invasive whole-body imaging of CAR
T cell in vivo distribution and fate is invaluable.
Long-term imaging is best achieved using re-
porter gene methodology, which also reliably re-
flects cell viability, particularly if employing a re-
porter like NIS that generates contrast based onits activity. The ideal reporter for cell tracking applications in human
settings is (1) detected with exquisite sensitivity using clinical imaging
modalities, (2) does not elicit immunogenic reactions, (3) shows very
limited endogenous expression and thus high specificity for traceable
cells, (4) can be detected with a widely available contrast agent, and
(5) does not confer any biological effect.
Our study is the first PET-afforded immune cell tracking study using
NIS as a non-immunogenic radionuclide reporter. While NIS has
been used as a reporter gene previously,24,28–33 only recently was it
employed for CAR T cell tracking, and then only using SPECT,17
which is more difficult to quantify than PET.We and others have pre-
viously shown cancer cell tracking by NIS-PET using the easily acces-
sible short half-life radiotracer [18F]BF4
–.30,33,34 We focused on PET
detection as clinical PET is currently the most sensitive imaging mo-
dality for cell tracking. A first-in-man study has recently reported
good contrast (for endogenous NIS expressing tissues such as the thy-
roid and stomach), generally low uptake in other organs, and safety of
[18F]BF4
–.35 NIS is a transporter and compared to tracer bindinglar Therapy Vol. 28 No 10 October 2020 2277
Figure 7. Ex Vivo Analyses of Additional MDA-MB-
231.GFP-CaaX Tumor-Bearing Cohorts
(A) Experimental scheme. (B) Ex vivo analysis of radioac-
tivity in harvested tissues from three different cohorts: ani-
mals that received T4NT CAR T cells intratumorally and
were sacrificed either on the day after administration (red) or
twoweeks later (light red), and control animals that received
untransduced T cells and were culled two weeks after
administration. Shown are cumulative quantified by g-
counting data from all animals. Signal levels after 15 days
were indistinguishable between animals that had received
CAR T cells and untransduced T cells (p = 0.4425) while
differences compared to day 1 were significant (p < 0.05 for
both); error bars are SD. (C) Immunofluorescence histology
demonstrating T4NT CAR T cell presence at injection sites
on day 1 after administration (by anti-human CD3 staining.
Tumor cells are visualized by GFP staining. Representative
micrographs are shown. Data in (B) and (C) confirm ob-
servations from Figure 6. (D) Typical magnified micrograph
of a MDA-MB-231.GFP-CaaX tumor on day 1 after T4NT
CAR T cell administration. It shows that T4NT CAR T cells
did not infiltrate into the adjacent tumor mass and a virtual
boundary (white dashed line) was drawn indicating the two
zones. Reduced GFP-CaaX signals in the area where T4NT
CAR T cells were present indicated loss of tumor cells in this
area. All scale bars in (C) and (D) are 100 mm.
Molecular Therapyreporters such as SSTR2 or PSMA intrinsically provides signal ampli-
fication. Importantly, NIS transport activity depends on the cellular
Na+/K+ gradient across the plasma membrane, which is fueled by
cellular ATP,36 thereby reflecting cell viability better than a reporter
which is detected based solely on its presence. This feature is impor-
tant for determining the fate of therapeutic cells in vivo.
Our data demonstrate not only that ectopic expression of NIS
was feasible and had no detrimental effects on anti-ErbB family
CAR T cells (Figure 2) but also that the use of NIS was safe for the
CAR T cells. We characterized viability, tumor cell killing capacity,
interferon-g release, and radiation damage for CAR T cells
that had been exposed to both the longer half-life NIS-
SPECT tracer [99mTc]TcO4
 and the shorter half-life NIS-PET tracer
[18F]BF4
– with complete decay of the radioisotopes in the cells before
analysis of CAR and reporter functions (Figure 3). DNA damage ex-
periments were performed at cellular radioactivity concentrations2278 Molecular Therapy Vol. 28 No 10 October 2020that were comparable (see Materials and
Methods) to amounts we had previously found
in vivo; values were calculated from quantitative
in vivo PET data obtained with [18F]BF4
 in
small cancer cell deposits.30 Notably, at the high-
est used concentrations (which were less than an
order of magnitude larger than what above calcu-
lations had yielded) there was DNA damage
detected in CAR T cells 2 h after radiotracer
administration. Importantly, our data also
demonstrated that radiation-induced damagewas repaired within 24 h with no long-lasting effects onto the CAR
T cells (Figures 3D and 3E). The obtained data clearly revealed that
both PET and SPECT radiotracers were feasible options for longitu-
dinal CAR T cell imaging with negligible damage to
administered CAR T cells through radionuclide imaging. Notably,
while [99mTc]TcO4
– is more available as it is generator-produced,
[18F]BF4
– has advantages over [99mTc]TcO4
 due to its shorter
half-life, its decay-dependent chemical decomposition, and because
PET is more sensitive than SPECT. Moreover, upcoming total-body
PET scanners will provide up to 40-fold increases in sensitivity over
current PET instrumentation.14
We applied our CAR T cell tracking approach to quantify CAR T cell
retention in vivo over time. While our in vivo traceable CAR T cells
had the capacity to home to tumors (e.g., MDA-MB-231 tumors as
shown in Figure S8), we chose to administer the CAR T cells intra-
tumorally to exclude variability caused by different kinetics or extent
Figure 8. Analysis of Immune Checkpoint and B7-Class Inhibitory Molecule Expression in MDA-MB-231 and MDA-MB-436 Models
(A) BCC lines were stained with antibodies directed against the indicated cell-surface proteins known to constitute one part of an immune checkpoint axis. Analysis was by
flow cytometry using (left) FMO controls to categorize cells into populations positive or negative for the indicated molecule, while (right) obtainedmean fluorescence intensities
(MFI; median) values were compared between cell lines. (B) Analysis as in (A) but for indicated B7-class inhibitory molecules. (A and B) Notably, additional molecules were
analyzed but if no differences were found between MDA-MB-231 and MDA-MB-436 cell lines, then data are shown in the Supplemental Information. For representative
corresponding histograms see Supplemental Information. Error bars represent SD; nR 3 different experiments. (C) Immunofluorescence staining for human PD-L1 in tumors
established from the indicated cell lines. (Top) Representative micrographs are shown; scale bars are 100 mm. (Bottom) Cumulative quantitative intensity analysis of tumor
tissues stained for anti-human PD-L1. Error bars are SD; n = 6 different tumors; all comparisons are significant (p < 0.0001 by ANOVAwith Tukey’s multiple comparison test)
except for controls (no primary and secondary antibody only; p = 0.6128), which was expected. Data demonstrated that in vitro differences in PD-L1 expression in these cell
lines were retained in orthotopic in vivo tumor models.
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Molecular Therapyof tumor targeting. Moreover, the intratumoral route is relevant
for this CAR, which is administered in this manner clinically
(NCT01818323). We performed in vivo tracking of anti-ErbB family
CAR T cells in two different orthotopic TNBC models and, unex-
pectedly, found a stark difference in CAR T cell retention between
MDA-MB-231 and MDA-MB-436 TNBC models (Figures 5 and
6). Retention differences inversely correlated with the expression
levels of PD-L1 expressed on the surface of these TNBC cells (Fig-
ure 8A), but PD-L1 was not the only differentially expressed im-
mune checkpoint molecule. Interestingly, we found differences in
the expression of the TIGIT ligands CD112 and CD155 (Figure 8A)
and the B7-class molecules B7-H3 and B7-H4 (Figure 8B) but not
for B7-H5/VISTA (Figure S11). Both CD112 and CD155 on tumor
cells but also antigen presenting cells (e.g., dendritic cells) can pro-
vide co-inhibitory signals to tumor-infiltrating T cells through TI-
GIT, which has been found to be expressed highly on CD8+
T cells in many cancers.37 Notably, CD226 competes with TIGIT
for binding of CD112 and CD155, but while CD226 binds with
lower affinity to these molecules than TIGIT, this interaction pro-
vides co-stimulatory signals.27 A high TIGIT-to-CD226 surface
expression ratio on regulatory T cells in the tumor microenviron-
ment has been correlated with a poor prognosis.38,39 TIGIT interac-
tions are complex and not fully understood, but our data showing a
higher percentage of MDA-MB-231 cells expressing CD112 and
fewer MDA-MB-231 cells expressing CD155 but at a significantly
higher level compared to CD155-expressing MDA-MB-436 cells,
provide an interesting anchor for further mechanistic studies. The
role of the ubiquitously expressed B7-H3 molecule in immune
evasion is somewhat controversial27 and while a large proportion
of both TNBC cell lines express this molecule, MDA-MB-231 cells
express less than MDA-MB-436 cells. In contrast, the cell-surface
expression and thus interaction capacity of B7-H4 has been found
to be tightly regulated40 and despite its receptor remaining elusive,27
it is interesting that we found its expression to be inversely corre-
lated to T4NT retention, and thus showing a similar correlation as
PD-L1 in our TNBC models.
Furthermore, we found that in MDA-MB-231 tumors, CAR T cells
killed tumor cells in their direct vicinity at injection sites but did not
infiltrate further into the tumor mass adjacent to injection sites (Fig-
ure 7). The tumor microenvironment has been extensively charac-
terized and found to be hostile to CAR T cells, on the one hand
because the glycolytic metabolism of tumor cells renders it hypoxic,
acidic, low in nutrients, and prone to oxidative stress,41 while on the
other hand multiple additional molecular and cellular factors
suppress the T cell immune response.18 CAR T cells are derived
from patients’ T cells; hence, they only differ from host T cells by
expression of the CARs but remain otherwise unaltered and conse-
quently responsive to the conditions in the tumor microenviron-
ment. The most pronounced difference in immune checkpoint in-
hibitor expression between out TNBC models was PD-L1
(Figure 8A). We found high-level PD-L1 expression in MDA-MB-
231 cells and much lower levels in MDA-MB-436 cells in vitro
and, importantly also ex vivo (Figure 8C). Notably, tumors are2280 Molecular Therapy Vol. 28 No 10 October 2020also capable of adaptive immune resistance, a reaction of cancer
cells resulting in the expression of molecules that actively turn off
an otherwise effective antitumor immune response.42 For example,
PD-L1 can be upregulated by cancer cells because of exposure to
T cell-derived interferon-g resulting in PD-1 expressing T cells to
be turned off, and the cancer cells evading destruction.43 MDA-
MB-231 cells have previously been reported to respond to inter-
feron-g by PD-L1 upregulation.44 We found that T4NT CAR
T cells were not retained in MDA-MB-231 tumors (Figure 6), while
we also found signs of them being functional initially within these
tumors (Figure 7). We also found in vitro that T4NT CAR T cells
produced interferon-g when co-cultured with MDA-MB-231 cells
(Figure 3C) and it is therefore not unlikely that this also happened
in vivo and contributed to MDA-MB-231 tumors not retaining
T4NT CAR T cells and thus not responding to treatment. In
contrast, MDA-MB-436 tumors retained the immunotherapy and
responded, hence it is unlikely that there was a major impact of
interferon-g-only-mediated adaptive immune resistance in this
model.
Preclinically, combining CARs with immune checkpoint inhibitors
has shown promising results. For example, CAR T cells engineered
to secrete anti-PD-L1 antibodies showed significantly improved activ-
ity compared to standard CAR T cells.45 Other studies demonstrated
enhanced anti-tumor activities by engineering CAR T cells to secrete
anti-PD-1.46,47 CAR T cells engineered to secrete PD-1 or PD-L1 an-
tibodies have been in clinical trials for EGFR, EGFRvIII, mucin-1, and
mesothelin expressing cancers.48 Our study was neither dedicated to
the development of a new CAR nor to discovery of precise CAR T cell
disarmingmechanisms, but instead to demonstrate in vivoCART cell
tracking by non-invasive and highly sensitive PET using a non-
immunogenic reporter. The revealed differences in tumor retention
in the two TNBCmodels serve as an application example and expand
the utility of in vivo CAR T cell tracking beyond tumor targeting to
the quantification of tumor retention. Notably, while we focused on
PD-L1 in our ex vivo analyses, our in vitro cell line data suggest
that additional other immune checkpoints, in particular TIGIT and
hitherto unknown receptor(s) binding to B7-H4, might be involved
in the observed CAR T cell retention differences. In summary, we
demonstrated the power of the imaging-guided approach for the pre-
clinical development of new or the optimization of existing CAR
T cell therapies.
Importantly, our NIS-based PET-afforded CAR T cell tracking
approach is directly translatable to the clinic. The platform is versa-
tile and, upon omission of the fluorescent protein RFP, fully
compliant with clinical translation. Importantly, clearance of the
NIS-PET radiotracer [18F]BF4
 from circulation is faster and,
crucially, completely reaches lower background levels compared to
radioactive iodide tracers for NIS.34 Tracking NIS expressing CAR
T cells in organs with high endogenous NIS expression, i.e. thyroid
and stomach, is not feasible and signals from these high-expressing
organs could potentially also affect low signals in the vicinity of
these organs. A potential solution, at least for regions close to the
www.moleculartherapy.orgstomach, would be oral administration of a substance absorbing ra-
diation, for example barium sulfate, which has long been in clinical
use as a CT contrast agent.49 Here, we also showed that radiotracer-
induced damage to CAR T cells during non-invasive imaging is
negligible, and therefore repeat-imaging is not a concern for func-
tion or survival of the administered traceable therapeutic cells. As
[18F]BF4
– can be produced in GMP-quality and as it has already
been used safely in humans,35 all components for NIS-afforded
CAR-T tracking by PET in humans are now available. It will be
beneficial by enabling spatiotemporal and non-invasive CAR-T
monitoring in patients providing information predictive of therapy
success (e.g. extent of CAR-T trafficking to tumors, kinetics of CAR-
T retention at lesions, heterogeneity of behavior between lesions,
CAR-T survival) and safety-relevant data (i.e. significant on-target
off-tumor accumulation). The latter will enable clinicians to control
infused cells, whereby CAR-T imaging will act as a biomarker and
trigger for cell therapy ablation via suicide gene technology.50 In
conclusion, NIS-afforded spatiotemporal CAR T cell tracking by
highly sensitive PET imaging is now realistically within reach for
human use.
MATERIALS AND METHODS
Information regarding the generation of constructs, adherent cells,
lentivirus production, flow cytometry, confocal microscopy, and
immunoblotting is detailed in the Supplemental Information.
Reagents
Reagents were from Merck, New England Biolabs, Sigma-Aldrich,
Thermo-Fisher or VWR unless otherwise stated. Tissue culture mate-
rials were from Corning, Sarstedt or TPP. [99mTc]TcO4
 was gener-
ator-eluted (on-site King’s Health Partners’ Radiopharmacy) as so-
dium salt solution and used within two half-lives. The NIS
radiotracer [18F]BF4
– was produced on the day of use as previously
described.30
Animals
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were purchased from
Charles River UK. All mice were maintained under sterile conditions
with food and water available ad libitum. All procedures were per-
formed in accordance with all legal, ethical, and institutional require-
ments (UK Home Office PPL 70/8879).
Isolation and Culture of Human T Cells
T cells were isolated from human peripheral blood donated by
anonymous healthy volunteers via the National Blood Service
(NHS Blood and Transplantation) with informed consent and
ethical approval from King’s College London Research Ethics
Committee (Study Reference HR-16/17-3746). Peripheral blood
mononuclear cells (PBMCs) were isolated by low-density centrifu-
gation on Ficoll (Sigma). T cells were cultured in RPMI 1640 con-
taining 5% (v/v) human serum (HS; BioSera), 2 mM L-glutamine
and 100 IU/mL penicillin/streptomycin at 37C in the presence of
5% (v/v) CO2 in a humidified incubator with admixtures as indi-
cated in the text. T cells were activated for 48 h with CD3/CD28-coated Dynabeads (1:1 bead:cell ratio) in growth medium and
cultured in 100 IU/ml IL-2 (untransduced T cells; IL-2 from Pro-
leukin-Novartis) or 30 ng/mL IL-4 (transduced T cells, cf. below;
IL-4 from Miltenyi Biotec) with growth media replenishment every
other day.Transduction of Human T Cells
Isolated T cells were thawed and cultured in normal growth medium
over night before being washed twice with growth medium contain-
ing 5 U/mL DNase I. 24 h later, T cells were activated with anti-CD3/
CD28 Dyna beads (3 106 cells/mL; 1:1 cell:bead ratio) and 24 h later
100 IU/mL IL-2 (Proleukin-Novartis) was added. Tissue culture
plates were coated with 50 mg/mL retronectin (TakaraBio) overnight
at 4C. On the next day, 5  105 T cells/well and lentiviruses were
added to retronectin-coated wells and plates were centrifuged at
350  g for 1 h at room temperature (RT). Transduced T cells were
incubated in growth medium supplemented with IL-4 (30 ng/mL;
Miltenyi Biotec) for selective expansion, while untransduced control
cells were cultured in growth medium with 100 IU/mL IL-2.
Cells were expanded and cultured for up to 21 d before administration
to mice.In Vitro Radiotracer Uptake in NIS-Expressing T Cells
106 indicated CAR T cells were transferred into Eppendorf tubes,
washed with ice-cold PBS, and resuspended in 1 mL growth medium.
100 kBq [99mTc]TcO4
 or 100 kBq [18F]BF4
were added to each tube
and cells were incubated for 30min at 37C in a humidified incubator.
Subsequently, cells were pelleted, supernatant was collected, and cells
were washed twice times with 1 mL PBS before being resuspended in
growth medium for g-counting and further culture if desired. Cells,
supernatants and wash solutions were subjected to radioactivity anal-
ysis using an automated g-counter with built-in decay correction
(1282 Compugamma, LKB-Wallac). The percentage of radioactivity
taken up by the cells was calculated according to Equation 1, wherein
Cpm represents decay-corrected radioactivity counts per minute.
%Radioactivity uptake =
Cpm ½Cells
Cpm ½Cells+Cpm ½Supernatant+Cpm½Wash1+Cpm½Wash2$100
(Equation 1)
Results of every uptake assay were normalized to a reference cell line,
which was run as an additional sample set. The reference cell line was
the previously used NIS reporter-expressing rat adenocarcinoma cell
line 3E.D.NIS.34T Cell Proliferation
5 104 untransduced T cells or CAR T cells (T4NT or T4DNT) were
plated in four 96-well-plates in 100 mL of cytokine supplemented me-
dia and incubated at 37C, 5% CO2 for up to 4 days (IL-2, 100 IU/mL
for T cells or IL-4, 30 ng/mL; 1 plate per day). Cell viability was
measured after addition and incubation of 44 mM Alamar Blue atMolecular Therapy Vol. 28 No 10 October 2020 2281
Molecular Therapy37C for 2 h. Individual plates were analyzed for fluorescence at
580 nm (emission; excitation at 530 nm) at each indicated time point.
Determination of T Cell Viability after Radiotracer Exposure
Untransduced T cells or CAR T cells (T4NT or T4DNT) were resus-
pended at 3  105 cells per 280 mL fully supplemented growth me-
dium. Either 20 mL PBS (control) or 20 mL containing 60 kBq of
one of the indicated NIS radiotracers ([18F]BF4
 or [99mTc]TcO4
)
were added and cells incubated for 72 h in a tissue culture incubator
in humidified air containing 5% (v/v) CO2. Reducing equivalents as a
measure of cell viability were then determined using the Alamar Blue
fluorescence assay (44 mM, 2 h, 37C; fluorescence readout at 530/
580 nm ex/em).
CAR T Cell Function by Cancer Cell Killing
Two independent assays were performed as indicated. BCC viability
assay was performed as follows: BCCs were seeded in a 96-well tissue
culture plate at 104 cells/100 mL growth medium/well and incubated
overnight. Next, 104 CAR T cells or untransduced T cells were added
in 100 mL growth medium per well with or without admixtures of 40
kBq [18F]BF4
 or [99mTc]TcO4
, and incubated for 72 h. CAR T Cells
or untransduced T cells were gently removed with the supernatant,
BCC were twice PBS-washed, and BCC viability was determined
with by Alamar Blue (44 mM, 2 h, 37C; fluorescence readout at
530/580 nm ex/em). Cell death assay was performed as follows:
BCCs were seeded in a 96-well tissue culture plate at 104 cells/
50 mL growth medium per well and incubated overnight. Untrans-
duced T cells or T4NT CAR-T cells were added at the indicated effec-
tor:target ratio. Cell death was measured using the CellTox Green
Cytotoxicity Assay (Promega) according to the manufacturer’s in-
structions. Plates were measured at 24 h and 48 h after starting the
co-culture using a GloMax-Multi Microplate Multimode Reader
(Promega; fluorescence readout at 490/520 nm ex/em).
CAR T Cell Function by Interferon-g Release
Experimental design was identical to cancer cell monolayer killing as-
says but for subsequent determination of interferon-g instead of can-
cer cell viability. Culture supernatants were collected and subjected to
analysis by interferon-g ELISA (Invitrogen; minimum detection
sensitivity 2 pg/mL) according to the manufacturer’s instructions.
Determination of Cellular DNA Damage
Cellular DNA damage is dependent on the type of radiation, the
amount of radioactivity in the cells and the intracellular distribution
(cf. distance to the vulnerable molecules). We adopted a function-
based approach to radiation effects and aimed to treat cells with
radioactivity amounts that were previously reached in non-invasive
imaging experiments designed to track cells using NIS as a reporter
gene. Small metastases from previous experiments served as the
closest available model for inferring radiotracer uptake in the envis-
aged CAR T cell deposits in this study. We previously found amounts
of up to 1.7 kBq/mL of [18F] BF4
– in small lungmetastases.30 T cell vol-
umes of healthy humans were found to be 166 mm3, (range
[126;216];51) equating to 6 million T cells fitting into 1 mL.2282 Molecular Therapy Vol. 28 No 10 October 2020Combining both numbers and omitting any other factors (e.g., pres-
ence of other cells, interstitial volumes, activated T cells being larger
than naive ones, etc.) this would result in 0.28 mBq/T cell. Above
factors would lead to less cells in this volume and thereby larger up-
take values, which we accommodated by performing experiments
such that up to 100-times higher radioactivity-per-cell values were
experimentally studied. The SPECT radiotracer [99mTc]TcO4

(25 MBq per mouse) is generally used at 5-times larger radioactivity
values during imaging than [18F] BF4
 (5 MBq per mouse). Assuming
similar in vivo behavior we used a 5-fold higher base for the experi-
ments, i.e., 1.4 mBq/T cell.
Untransduced T cells or T4NT CAR T cells were resuspended at 106
cells/mL in growth medium and incubated in the presence of either
1.5 MBq, 500 kBq, 150 kBq, or 50 kBq of [18F]BF4
 or 9 MBq, 3
MBq, 1 MBq, or 300kBq [99mTc]TcO4
 for 30 min at 37C, followed
by analysis of cellular radioactivity uptake as described above. Resul-
tant cellular radioactivity amounts are indicated in each correspond-
ing figure legend and were 120-, 50-, 21-, and 7-times ([18F]BF4
) or
were 92, 36, 3.5, and 2 times ([99mTc]TcO4
) larger than estimated to
be reached during non-invasive imaging (see above). Cells were then
resuspended in growth medium in a poly-L-lysine-coated 96-well
plate, centrifuged at 650  g for 10 min, and incubated until fixing
with 4% (w/v) paraformaldehyde (ice-cold, 15 min) at indicated
time points (times indicate period from start of radioactive uptake un-
til fixation). Fixed samples were kept at 4C until staining for double-
strand DNA breaks using an anti-gH2AX antibody. Subsequently,
cells were permeabilized in 0.5% Triton X-100/0.5% IGEPAL CA-
640, blocked with 1% donkey serum in 2% BSA for 1 h, incubated
with a monoclonal mouse anti-gH2AX antibody (Ser139; clone
JBW301 from Merck 05-636; 1:1,600 in 3% BSA), and stained with
a donkey anti-mouse-Alexa Fluor 488 secondary antibody (Jackson
ImmunoResearch 715-545-150; 0.5 mg/mL in 3% BSA) and Hoechst
33342 (1 mg/mL). Images were acquired on an Operetta CLS system
(PerkinElmer) and analyzed by the Harmony v4.1 software using
an automated analysis pipeline enabling the identification of
gH2AX foci in nuclei of NIS-RFP-expressing CAR T cells or untrans-
duced T cells; >35 nuclei per replicate were analyzed as a minimum
for each condition.
Determination of Detection Sensitivity of Traceable CAR T Cells
To determine the detection sensitivity of NIS-RFP expressing trans-
duced T cells in the nanoPET/CT scanner (Mediso), we prepared
cell pellets consisting of pre-labeled NIS-RFP-positive (57 ± 3 mBq
[99mTc]TcO4
/cell) and NIS-RFP-negative untransduced T cells.
The total cell number per pellet was kept constant at 106 cells. This
procedure has previously been used to determine the detection limit
of reporter gene expressing cells in preclinical SPECT and PET instru-
ments.24,34 Briefly, cell mixtures were prepared in 50 mL PBS+/+ in
Eppendorf Tubes, pelleted, and immediately scanned in the nano-
SPECT/CT equipment for 30 min. Reconstructed images were
analyzed using Vivoquant software, whereby radioactivity was
measured in volumes of interest drawn with the help of CT informa-
tion (tube walls as boundaries). Measurements were performed in
www.moleculartherapy.orgtriplicate. In line with standard analytical procedures, we defined the
limit of detection (LOD) to be three times the standard deviation
above background signals (Figure S3).
TNBC Xenograft Models
Young adult (5- to 6-week-old) female NSG mice were used to
establish orthotopic mammary tumors with the indicated breast
cancer cell lines (106 cells injected into the mammary fat pad). Tu-
mors were monitored using callipers. Five million CAR T cells or
vehicle were administered intratumorally in animals bearing tumors
of 50 mm3 volume (animals were randomly allocated to cohorts).
In Vivo Imaging and Image Analysis
Mice were anesthetized with 2% (v/v) isoflurane/O2 and received 5
MBq [18F]BF4
 (i/v in 100 mL sterile PBS) prior to PET/CT imaging
(NanoPET/CT; Mediso). After radiotracer administration, animals
were placed anaesthetized onto scanner beds and CT was performed
(55 kVp tube voltage, 1,200 ms exposure time, 360 projections).
40 min after radiotracer administration, animals were PET imaged.
Repeat imaging with the same radiotracer was not affected by tracer
amounts from prior imaging sessions due to the short radioactive
half-life of 18F (110 min).34 PET/CT data were reconstructed using
Tera-Tomo (Mediso) with corrections for attenuation, detector
dead time, and radioisotope decay in place as needed. All images
were analyzed using VivoQuant software (inviCRO) enabling the
delineation of regions of interest (ROIs) for quantification of radioac-
tivity. CT images were used to draw ROIs and provide the volumes
required for standard uptake value calculations. The total activity in
the whole animal (excluding the tail) at the time of tracer administra-
tion was defined as the injected dose (ID).
Ex Vivo Tissue Analyses
For analysis of radioactivity in harvested tissues, tissues were weighed,
and radioactivity was quantified using a g-counter (1282-Compu-
gamma, LKB-Wallac), together with calibration standards. Data
were expressed as %ID/g. For histology, tumors were harvested and
frozen in Optimal Cutting Temperature Medium (OCT) followed
by tissue sectioning (5 mm). Thawed sections were fixed in 4% PFA
in PBS for 10 min, permeabilized (0.2% [v/v] Triton X-100/PBS),
washed, and blocked (PBS containing 2% [v/v] goat serum, 0.1%
fish skin gelatin and 0.2% [v/v] Tween-20) before being incubated
with the indicated combinations of the following primary antibodies
(2 mg/mL) overnight at 4C: anti-human CD3 (monoclonal rabbit;
[SP7], Abcam) and anti-PD-L1 (monoclonal rabbit; [28-8]; Abcam).
After three PBS washes, sections were then stained with the corre-
sponding secondary antibody (1 mg/mL) for 45 min at RT in the
dark: goat anti-rabbit-Cy5, (Jackson ImmunoResearch). Nuclei
were stained with Hoechst 33342 (1 mg/mL in PBS; 15 min at RT).
Sections were washed twice with PBS and deionized water each before
being mounted onto microscope slides using Mowiol-488 containing
2.5% DABCO. All solutions were sterile filtered before use. Samples
were dried overnight in the dark and imaged on a Nikon Eclipse
Ti2 wide-field fluorescence microscope equipped with the following
filter sets (ex/em; all BP) for imaging Hoechst 33342 (AT350/50;T400lp; ET460/50 m), GFP/Alexa 488 (ET470/40; T495lpxr;
ET525/50 m), TagRFP (ET539/21; T556lpxr; ET576/31 m) and
Cy5/Alexa 647 (ET640/30; T660lpxr; ET690/50 m). Fiji/ImageJ
v1.5 software was used for all analyses.
Statistical Analysis
Statistical analysis was performed using Prism v7 software (Graph-
Pad) with details added to figure legends and text.
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